ERBB2 and breast cancer: Neratinib, which has been validated in combination with Capecitabine in advanced or metastatic HER-2+ BC [46,48,49,50], has resulted in a higher rate of pathological complete response (pCR) in comparison to TZ plus chemotherapy [48].